Nuzenio

Advances Bispecific Adc

Advances Bispecific Adc news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 8 latest news signals 8 publisher sources 100/100 entity strength

Latest news

Promatix secures Innovate UK grant to advance cis-bispecific ADC programme - Manufacturing ChemistManufacturing Chemist · Tue, 04 Aug 2026 12:14:55 GMTPromatix secures Innovate UK funding to advance bispecific ADC programme - PharmafilePharmafile · Mon, 03 Aug 2026 10:31:13 GMTPromatix Biosciences Awarded Innovate UK Biomedical - GlobeNewswireGlobeNewswire · Tue, 28 Jul 2026 07:30:00 GMTVERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb - The Manila TimesThe Manila Times · Mon, 27 Jul 2026 11:17:21 GMTVERAXA Biotech Announces Advancement of VXA-222 Bispecific ADC Program in Collaboration with OmniAb - quiverquant.comquiverquant.com · Mon, 27 Jul 2026 11:13:00 GMTVeraxa Advances Bispecific ADC Candidate VXA-222 Following OmniAb Discovery Milestone - BioPharm InternationalBioPharm International · Mon, 27 Jul 2026 07:00:00 GMTVERAXA Biotech (VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - Yahoo FinanceYahoo Finance · Mon, 27 Jul 2026 07:00:00 GMTVERAXA’s VXA-222 Uses One Molecule to Address Two Tumor Antigens - Stock TitanStock Titan · Mon, 27 Jul 2026 07:00:00 GMT

Timeline

Tue, 04 Aug 2026 12:14:55 GMTPromatix secures Innovate UK grant to advance cis-bispecific ADC programme - Manufacturing Chemist
Mon, 03 Aug 2026 10:31:13 GMTPromatix secures Innovate UK funding to advance bispecific ADC programme - Pharmafile
Tue, 28 Jul 2026 07:30:00 GMTPromatix Biosciences Awarded Innovate UK Biomedical - GlobeNewswire
Mon, 27 Jul 2026 11:17:21 GMTVERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb - The Manila Times
Mon, 27 Jul 2026 11:13:00 GMTVERAXA Biotech Announces Advancement of VXA-222 Bispecific ADC Program in Collaboration with OmniAb - quiverquant.com
Mon, 27 Jul 2026 07:00:00 GMTVeraxa Advances Bispecific ADC Candidate VXA-222 Following OmniAb Discovery Milestone - BioPharm International

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Advances Bispecific Adc.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

8 distinct publisher/source names are currently connected to this entity page.